BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si’s novel proteomics platform, Proteus™.

康涅狄格州布兰福德（BUSINESS WIRE）--Quantum Si Incorporated（纳斯达克：QSI）（“Quantum Si”，“QSI”或“公司”）、Protein Sequencing Company™和Planet Innovation今天宣布，他们将合作开发和制造Quantum Si的新型蛋白质组学平台Proteus™。

Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract manufacturer for Quantum-Si’s Platinum® Pro instrument, set to debut in the first half of 2025.

。目前，Planet Innovation是Quantum Si Platinum®Pro仪器的合同制造商，该仪器将于2025年上半年首次亮相。

Through this expanded partnership, Planet Innovation will support the development of Quantum-Si’s Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization..

通过这种扩大的合作关系，Planet Innovation将支持Quantum Si的Proteus仪器的开发，并作为合同制造合作伙伴，确保从开发到商业化的无缝过渡。。

“We are thrilled to expand our partnership with Planet Innovation and leverage their global scale and expertise to accelerate the development and commercialization of Proteus,” said Jeff Hawkins, President and CEO of Quantum-Si. “We believe that partnering with Planet Innovation will allow us to deliver this novel instrument to the market on a timeline of under two years.”.

Quantum Si总裁兼首席执行官杰夫·霍金斯（Jeff Hawkins）表示：“我们很高兴扩大与Planet Innovation的合作伙伴关系，利用其全球规模和专业知识加速Proteus的开发和商业化。我们相信，与Planet Innovation的合作将使我们能够在不到两年的时间内将这种新型仪器推向市场。”。

“Planet Innovation is proud to support Quantum-Si in developing their new proteomics platform. We have a large, established team with a proven track record in developing world-first life science platforms that are disruptive, compliant and commercialized in record time. We are excited to work side-by-side with the Quantum-Si team in making proteomics more accessible to researchers, scientists and clinicians to ultimately improve human health,” said Stuart Elliott, CEO and co-founder of Planet Innovation..

“Planet Innovation以支持Quantum Si开发其新的蛋白质组学平台为荣。我们拥有一支庞大的、成熟的团队，在开发世界上第一个生命科学平台方面有着良好的记录，这些平台具有颠覆性、合规性和创纪录的商业化。我们很高兴与Quantum Si团队携手合作，使研究人员、科学家和临床医生更容易获得蛋白质组学，最终改善人类健康，”Planet Innovation首席执行官兼联合创始人斯图尔特·埃利奥特（Stuart Elliott）表示。。

About Quantum-Si Incorporated

关于Quantum Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools.

蛋白质测序公司Quantum Si专注于彻底改变蛋白质组学的发展领域。该公司的Platinum®仪器使下一代蛋白质测序™能够推进蛋白质组学研究，药物发现和诊断，超越现有蛋白质组学工具的可能性。

Learn more at quantum-si.com or follow us on LinkedIn or X..

请访问quantum-si.com了解更多信息，或在LinkedIn或X上关注我们。。

Forward Looking Statements

前瞻性声明

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events.

本新闻稿包括1995年《美国私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。公司的实际结果可能与其预期、估计和预测不同，因此，您不应将这些前瞻性陈述视为对未来事件的预测。

Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements.

诸如“预期”、“估计”、“项目”、“预算”、“预测”、“预期”、“打算”、“计划”、“可能”、“会”、“可能”、“应该”、“相信”、“预测”、“潜在”、“继续”等词语以及类似表达（或此类词语或表达的负面版本）旨在识别此类前瞻性陈述。

These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements.

这些前瞻性报表包括但不限于公司对未来业绩以及产品和服务的开发和商业化的预期，其预期现金跑道以及2024年全年的财务指导。这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。

Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adopti.

这些因素大多不在公司的控制范围内，很难预测。可能导致此类差异的因素包括但不限于：无法维持公司A类普通股在纳斯达克股票市场的上市；公司盈利增长和管理增长并留住关键员工的能力；公司正在进行的领导层过渡；适用法律法规的变更；公司未来融资的能力；公司产品开发和商业化活动的成功、成本和时间安排；商业化和采用。